“The COVID-19 pandemic has demonstrated why all countries need to have a sustainable vaccine strategy in place, not just reliant on donations, to access effective and affordable vaccines, tests, and treatments, with systems to distribute them efficiently and equitably for the broader population.
As global economies continue to feel the aftershocks of this pandemic, biosimilar product creation will be a critical component of a post-COVID-19 health system both in terms of expanding access to biologic therapies, providing patient and physician choice, and addressing healthcare budgets.
Another post-pandemic challenge, for us in America, is to secure sufficient quantities of essential and critical medical supplies with a more reliable and sustainable mechanism. As shown by the drug shortages in our country, the PDTi business model can be utilized to meet this growing challenge.”
“Our wounds are often the openings into the best and most beautiful part of us.”
– Dr. Robert Redfield, M.D.
